333
Participants
Start Date
December 10, 2019
Primary Completion Date
October 30, 2026
Study Completion Date
May 12, 2027
INBRX-106 - Hexavalent OX40 agonist antibody
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
pembrolizumab 200 mg
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
pembrolizumab 400 mg
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Carboplatin AUC-5
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
Carboplatin AUC-6
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
Pemetrexed 500 mg/m2
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles
Cisplatin 75mg/m2
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
Paclitaxel 200mg/m2
paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
Nab paclitaxel 100mg/m2
Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
Winship Cancer Institute - Emory University, Atlanta
RECRUITING
Mid Florida Hematology and Oncology Center, Orange City
RECRUITING
Clermont Oncology Center, Clermont
RECRUITING
Vanderbilt University School of Medicine, Nashville
RECRUITING
Norton Cancer Institute, Louisville
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Barbara Ann Karmanos Cancer Institute, Detroit
RECRUITING
Henry Ford Cancer Institute, Detroit
RECRUITING
START Midwest, Grand Rapids
RECRUITING
University of Iowa, Iowa City
RECRUITING
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
RECRUITING
HealthPartners Cancer Research Center (Regions Hospital), Saint Paul
RECRUITING
HealthPartners Cancer Research Center, Saint Louis Park
RECRUITING
Intermountain Health Cancer Centers of Montana, Billings
RECRUITING
The University of Chicago Medical Center, Chicago
RECRUITING
Nebraska Cancer Specialists, Omaha
RECRUITING
Mary Crowley Cancer Research, Dallas
RECRUITING
The University of Texas Health Science Center at Tyler, Tyler
COMPLETED
Renovatio Clinical, The Woodlands
COMPLETED
NEXT Oncology, San Antonio
COMPLETED
Renovatio Clinical - El Paso, El Paso
RECRUITING
California Research Institute, Los Angeles
RECRUITING
Valkyrie Clinical Trials, Los Angeles
RECRUITING
City of Hope, Duarte
RECRUITING
Los Angeles Cancer Network, Glendale
RECRUITING
Valkyrie Clinical Trials, Murrieta
RECRUITING
Providence Medical Foundation, Santa Rosa
RECRUITING
Providence Portland Medical Center, Portland
RECRUITING
Curie Oncology, Singapore
RECRUITING
Icon Cancer Centre Farrer Park, Singapore
RECRUITING
Icon Cancer Centre Mount Alvernia, Singapore
RECRUITING
The Catholic University of Korea, St. Vincent's Hospital, Gyeonggi-do
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Severance Hospital, Yonsei University Health System, Seoul
RECRUITING
The Catholic University of Korea Seoul St. Mary's Hospital,, Seoul
RECRUITING
Changhua Christian Hospital (CCH), Changhua
RECRUITING
E-Da Cancer Hospital, Kaohsiung City
RECRUITING
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH), Kaohsiung City
RECRUITING
National Cheng Kung University Hospital, Tainan City
RECRUITING
Taipei Veterans General Hospital, Taipei
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Inhibrx Biosciences, Inc
INDUSTRY